The p16INK4A or the p53 pathways are frequently mutated in glioblastoma [57], [58], [59], however we have currently no indication that transgenic over expression of Bmi1 contributes to the development of glioma/glioblastoma, although other or additional predisposing lesions might enable this. Here, CDKN2A is linked to central nervous system cancer.